<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01336985</url>
  </required_header>
  <id_info>
    <org_study_id>110131</org_study_id>
    <secondary_id>11-CC-0131</secondary_id>
    <nct_id>NCT01336985</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads</brief_title>
  <official_title>Phase Ib Study of the Safety and Pharmacokinetics of Chemoembolization With Irinotecan-Eluting Beads for the Treatment of Hepatic Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Cancers in other parts of the body often spread to the liver, developing tumors which in&#xD;
           many instances cannot be removed with surgery. Liver chemoembolization is a treatment&#xD;
           that is routinely performed to control liver tumors in those who cannot have surgery. It&#xD;
           has been shown to prolong survival, but does not cure the cancer. During&#xD;
           chemoembolization very tiny beads (drug-eluting beads, or DEB) containing chemotherapy&#xD;
           drugs (usually doxorubicin) are administered directly into the blood vessels of a liver&#xD;
           tumor. The drug within the beads is then released into the tumor whilethe beads&#xD;
           temporarily interrupt the tumor s blood supply.&#xD;
&#xD;
        -  Irinotecan, a drug commonly given intravenously to treat colon cancer, has been given in&#xD;
           chemoembolization procedures in four other studies that have shown that the treatment is&#xD;
           generally well tolerated. Researchers are interested in determining whether giving the&#xD;
           drug irinotecan directly into the liver using drug-eluting beads is not only well&#xD;
           tolerated but also provides a larger dose directly to the tumor as determined by tumor&#xD;
           and normal liver tissue biopsies. The liver biopsies are an optional portion of the&#xD;
           study.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To evaluate the safety and effectiveness of chemoembolization with irinotecan for tumors&#xD;
      caused by cancer that has spread to the liver.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals at least 18 years of age who have melanoma, colon, or another intra-abdominal&#xD;
      cancer that has spread to the liver.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical examination, medical history, blood tests,&#xD;
           tumor imaging studies, and liver biopsies.&#xD;
&#xD;
        -  Participants will receive up to 3 DEB chemoembolization treatments about 6 weeks apart.&#xD;
&#xD;
        -  After two treatments, participants will have imaging studies to see if the tumors have&#xD;
           shrunk, and those whose tumors have shrunk may have a third treatment.&#xD;
&#xD;
        -  Multiple liver biopsies may be performed and blood samples will be taken to determine&#xD;
           how much drug is in the tumor and the circulation, and to see how the tumor reacts to&#xD;
           the drug.&#xD;
&#xD;
        -  Participants will return for followup visits for up to 1 year....&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Clinical evidence suggests that hepatic chemoembolization may prolong survival in&#xD;
           patients with hepatic metastases.&#xD;
&#xD;
        -  Early studies have indicated that chemoembolization using irinotecan drug eluting beads&#xD;
           may be more effective in treating hepatic metastases from colon or melanoma primary&#xD;
           tumors.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Primary Objective:&#xD;
&#xD;
           --To determine the safety of hepatic chemoembolization with drug-eluting beads&#xD;
           containing 100mg of irinotecan&#xD;
&#xD;
        -  Secondary Objectives:&#xD;
&#xD;
             -  To determine the serum pharmacokinetics and tumor tissue concentrations achieved&#xD;
                following hepatic chemoembolization with irinotecan-eluting beads&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Patients &gt; 18 years of age with pathologically proven hepatic metastases from the&#xD;
           gastrointestinal tract, or melanoma with unresectable hepatic lesions.&#xD;
&#xD;
        -  Patients whose extent of hepatic metastases represents &lt;60% of total liver volume AND&#xD;
           whose extrahepatic metastatic disease is determined to be minimal&#xD;
&#xD;
        -  Patients must be ECOG performance status of less than or equal to 2 and a life&#xD;
           expectancy of more than 3 months.&#xD;
&#xD;
        -  Patients must have adequate organ function.&#xD;
&#xD;
        -  Patients must not have had chemotherapy, radiation therapy, or biological therapy for at&#xD;
           least 4 weeks prior to starting study treatments.&#xD;
&#xD;
        -  Patients are not to receive conventional chemotherapy or therapeutic monoclonal&#xD;
           antibodies while on study.&#xD;
&#xD;
        -  Patients must not have an acute, critical illness.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  A Phase Ib trial in which patients undergo hepatic chemoembolization with drug-eluting&#xD;
           beads containing 100mg irinotecan.&#xD;
&#xD;
        -  Up to 15 patients will be enrolled over 1 year to accrue 10 evaluable patients.&#xD;
&#xD;
        -  Patients will undergo up to 3 chemoembolizations.&#xD;
&#xD;
        -  Following chemoembolization, patients will have serial serum pharmacokinetic samples&#xD;
           drawn and tumor biopsies in order to measure serum and tumor tissue concentrations of&#xD;
           irinotecan&#xD;
&#xD;
        -  Patients will be followed for one year after completion of the last treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>March 28, 2011</start_date>
  <completion_date type="Actual">March 28, 2011</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety of hepatic chemoembolization with drug-eluting beads containing 100mg of irinotecan</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the serum pharmacokinetics and tumor tissue concentrations achieved following hepatic chemoembolization with irinotecan-eluting beads</measure>
  </secondary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Neoplasm Metastases</condition>
  <condition>Melanoma</condition>
  <condition>Colorectal Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chemoembolization</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug-Eluting Beads</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
          -  Patients with pathologically proven hepatic-dominant metastases from abdominal or&#xD;
             gastrointestinal tract primary malignancy or melanoma where the life limiting&#xD;
             component of the disease is hepatic metastasis&#xD;
&#xD;
          -  Patients must have unresectable hepatic lesions or must be unable or unwilling to&#xD;
             undergo surgical resection. Patients may have undergone prior wedge resection of the&#xD;
             liver for metastatic disease&#xD;
&#xD;
          -  All patients must be refractory to or intolerant of approved standard systemic&#xD;
             therapy.&#xD;
&#xD;
        Specifically:&#xD;
&#xD;
          -  Patients with metastatic colorectal must have received 5-FU and leucovorin in&#xD;
             combination with either oxaliplatin and/or irinotecan, since level 1 evidence support&#xD;
             increase survival with these regimens, compared to 5-FU and leucovorin alone.&#xD;
&#xD;
          -  Patients with melanoma must have received IL-2 or other immunotherapy options (such as&#xD;
             ipilimumab or adoptive cell therapy) that have been reported to have efficacy.&#xD;
&#xD;
               -  Patients with extrahepatic metastases or an unresected primary lesion will be&#xD;
                  considered eligible if the extrahepatic disease is minimal&#xD;
&#xD;
               -  Extent of hepatic metastases is &lt;60% of total hepatic volume.&#xD;
&#xD;
               -  Patients must have at least one lesion that can be readily biopsied (at least&#xD;
                  10mm diameter)&#xD;
&#xD;
               -  ECOG performance status less than or equal to 2&#xD;
&#xD;
               -  Life expectancy &gt; 3 months&#xD;
&#xD;
               -  At least 18 years of age&#xD;
&#xD;
               -  Age &lt; 85 years&#xD;
&#xD;
               -  Patients must have had no chemotherapy, radiotherapy, or biologic therapy for&#xD;
                  their malignancy for at least 4 weeks (or until response can be adequately&#xD;
                  assessed) prior to treatment and must have recovered from all clinically&#xD;
                  significant side effects of therapeutic and diagnostic interventions. Anti-VEGF&#xD;
                  agents (eg, Avastin) may not be administered less than 4 weeks prior to DEB-TACE&#xD;
                  treatment.&#xD;
&#xD;
               -  Patients are not to receive conventional chemotherapy or therapeutic monoclonal&#xD;
                  antibodies while receiving protocol treatment&#xD;
&#xD;
               -  Hematology:&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1500/mm(3) without the support of Filgrastim.&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm(3).&#xD;
&#xD;
          -  Hemoglobin greater than 8.0 g/dl.&#xD;
&#xD;
             -Chemistry:&#xD;
&#xD;
          -  Serum ALT/AST less than or equal to 3 times the upper limit of normal.&#xD;
&#xD;
          -  Serum creatinine less than or equal to 2.0 mg/dl unless the measured creatinine&#xD;
             clearance is greater than 60 mL/min&#xD;
&#xD;
          -  Total bilirubin less than or equal to 2 mg/dl.&#xD;
&#xD;
          -  INR &lt;1.5&#xD;
&#xD;
          -  PTT less than or equal to 1.3 times control unless a mixing study confirms the&#xD;
             presence of a lupus anticoagulant as the cause for the prolonged PTT.&#xD;
&#xD;
               -  Screening electrocardiogram is normal with QTc less than or equal to 480msec).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Significant cardiac or pulmonary insufficiency as evidenced by&#xD;
&#xD;
               -  history of congestive heart failure with an LVEF &lt; 40%&#xD;
&#xD;
               -  history of COPD or other chronic pulmonary disease with PFT s indicating an FEV1&#xD;
                  less than 30% or a DLCO less than 40% predicted for age&#xD;
&#xD;
          -  Portal Vein Occlusion or other contraindications to chemoembolization&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Prior chemoembolization therapy&#xD;
&#xD;
          -  Prior precutaneous hepatic perfusion therapy&#xD;
&#xD;
          -  Prior selective internal radiation therapy (SIRT) with Yttrium-90&#xD;
&#xD;
          -  Prior biliary diversion surgery&#xD;
&#xD;
          -  Previous liver resection other than wedge resection.&#xD;
&#xD;
          -  Pregnant patients and nursing mothers will be excluded because of the unknown effects&#xD;
             of this therapy on the fetus or nursing infants.&#xD;
&#xD;
          -  Patients taking immunosuppressive drugs or requiring ongoing chronic anticoagulation&#xD;
             will not be eligible.&#xD;
&#xD;
          -  Patients with active bacterial infections with systemic manifestations (malaise,&#xD;
             fever, leucocytosis) are not eligible until completion of appropriate therapy.&#xD;
&#xD;
          -  Patients with severe allergic reactions to iodine contrast which cannot be controlled&#xD;
             by premedication with antihistamines and steroids are not eligible as a hepatic&#xD;
             angiogram is needed for this procedure.&#xD;
&#xD;
          -  Patients with a known prior hypersensitivity reaction or other contraindication to&#xD;
             irinotecan will be excluded.&#xD;
&#xD;
          -  Patients taking phenytoin, phenobarbital, carbamazepine, rifampin, rifabutin, St. John&#xD;
             s Wort, or other CYP3A inducers or inhibitors are not eligible for this study.&#xD;
&#xD;
          -  Patients are prohibited from receiving other experimental agents/adjuvant treatments&#xD;
             during the study.&#xD;
&#xD;
          -  Patients with more than one active primary malignancy, except for basal cell carcinoma&#xD;
             or superficial bladder neoplasia, are to be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot B Levy, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Gh√©mard O, Levi F, Bismuth H. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004 Oct;240(4):644-57; discussion 657-8.</citation>
    <PMID>15383792</PMID>
  </reference>
  <reference>
    <citation>Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol. 2003;14 Suppl 2:ii13-6. Review.</citation>
    <PMID>12810452</PMID>
  </reference>
  <reference>
    <citation>Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res. 2006 Sep-Oct;26(5B):3793-5.</citation>
    <PMID>17094403</PMID>
  </reference>
  <verification_date>November 3, 2014</verification_date>
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>December 14, 2019</last_update_submitted>
  <last_update_submitted_qc>December 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <keyword>Chemoembolization</keyword>
  <keyword>Hepatic Metastases</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Drug Eluding Beads</keyword>
  <keyword>Colorectal Cancer</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>Hepatic Cancer</keyword>
  <keyword>Melanoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

